Xencor, Inc.

XNCR • Biotechnology

$25.16

▲ +0.22 (+0.88%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$1.91B

Growth

10.6%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.3Healthy liquidity · 6.25Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:06 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$25.16

Change0.88%

Shares Out75.86M

Market Cap$1.91B

Enterprise Value$1.45B

52W Range6.92 - 21.96

Beta0.86

P/E-11.69

P/S18.18

P/B3.79

P/FCF-6.90

EV/Sales13.83

Price$25.16

Change0.88%

Shares Out75.86M

Market Cap$1.91B

Enterprise Value$1.45B

52W Range6.92 - 21.96

Beta0.86

P/E-11.69

P/S18.18

P/B3.79

P/FCF-6.90

EV/Sales13.83

EV/EBITDA-18.73

EV/FCF-5.25

Earnings Yield-8.56%

FCF Yield-14.49%

Dividend Yield0.00%

Gross Margin91.63%

Oper. Margin-141.35%

Profit Margin-73.20%

Debt/Eq0.30

Current Ratio6.25

Quick Ratio6.25

Revenue 5Y10.65%

Target$34.40

Target Upside36.72%

Target Median$35.00

Target Range20.00 - 46.00

Volume982.61K

Avg Volume907.51K

EPS Surprise-1.06

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

58/100

Why this score▼

Manageable debt level · 0.3Healthy liquidity · 6.25Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

XNCR

Analyst sentiment

Based on 28 analyst votes · 2026-10-22

93/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$20.00

Mean

$30.33

Median

$27.00

High

$44.00

Company Overview

IPO: 12/3/2013

Industry: Biotechnology

P/B i: 3.79

Debt / Equity i: 0.30

Operating Margin: -141.35%

Net Margin: -73.20%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.30

Current Ratio: 6.25

Quick Ratio: 6.25

Status: Good

Insider Transactions

Recent executive and insider activity

Deshaies Raymond Joseph

Transaction: 06/16/2026

BUY

Change

+10,302

Price

Not reported

Filing

07/08/2026

Type

BUY

Deshaies Raymond Joseph

Transaction: 06/16/2026

BUY

Change

+20,604

Price

$12.20

Filing

07/08/2026

Type

BUY

SIMPSON TODD E

Transaction: 06/16/2026

BUY

Change

+20,604

Price

$12.20

Filing

07/08/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Deshaies Raymond Joseph	BUY	+10,302	Not reported	06/16/2026	07/08/2026
Deshaies Raymond Joseph	BUY	+20,604	$12.20	06/16/2026	07/08/2026
SIMPSON TODD E	BUY	+20,604	$12.20	06/16/2026	07/08/2026
SIMPSON TODD E	BUY	+10,302	Not reported	06/16/2026	07/08/2026
RANIERI RICHARD J	BUY	+20,604	$12.20	06/16/2026	07/08/2026
RANIERI RICHARD J	BUY	+10,302	Not reported	06/16/2026	07/08/2026
Montgomery Alan Bruce	BUY	+20,604	$12.20	06/16/2026	07/08/2026
Montgomery Alan Bruce	BUY	+10,302	Not reported	06/16/2026	07/08/2026
Klencke Barbara	BUY	+20,604	$12.20	06/16/2026	07/08/2026
Klencke Barbara	BUY	+10,302	Not reported	06/16/2026	07/08/2026
GUSTAFSON KURT A	BUY	+20,604	$12.20	06/16/2026	07/08/2026
GUSTAFSON KURT A	BUY	+10,302	Not reported	06/16/2026	07/08/2026
GORMAN KEVIN CHARLES	BUY	+20,604	$12.20	06/16/2026	07/08/2026
GORMAN KEVIN CHARLES	BUY	+10,302	Not reported	06/16/2026	07/08/2026
Feigal Ellen	BUY	+20,604	$12.20	06/16/2026	07/08/2026
Feigal Ellen	BUY	+10,302	Not reported	06/16/2026	07/08/2026
Feigal Ellen	SELL	-6,843	$13.06	06/18/2026	06/22/2026
Montgomery Alan Bruce	SELL	-5,064	$12.31	06/15/2026	06/17/2026
RANIERI RICHARD J	SELL	-5,474	$12.31	06/15/2026	06/17/2026
GUSTAFSON KURT A	SELL	-5,474	$12.31	06/15/2026	06/17/2026

About the Company

Xencor, Inc.

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

Source - link

Peers

ANAB BBOT KOD MNMD NKTR NRIX OCS PHAT TNGX URGN

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC). The live webcast of the conference call may.

Business Wire

Xencor (NASDAQ:XNCR) Shares Up 4.6% – What’s Next?

Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) were up 4.6% during mid-day trading on Monday. The company traded as high as $24.66 and last traded at $24.8920. 290,326 shares were traded during trading, a decline of 69% from the average daily volume of 949,940 shares. The stock had previously closed at $23.80. Analyst

Defense World

Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE

Bank of America Corp DE bought a new stake in shares of Xencor, Inc. (NASDAQ: XNCR) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 360,396 shares of the biopharmaceutical company's stock, valued at approximately $5,802,000. Bank of America Corp DE owned 0.48% of

Defense World

Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast

Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings. Valuation and Earnings This table compares Anika Therapeutics

Defense World

Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR

Bank of New York Mellon Corp acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 410,769 shares of the biopharmaceutical company's stock, valued at approximately $6,613,000. Bank

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-06	-0.65	-1.71	-1.06
2026-02-25	-0.64	-0.09	0.55
2025-11-05	-0.72	-0.08	0.64
2025-08-06	-0.78	-0.41	0.37
2025-05-07	-0.63	-0.66	-0.03
2025-02-27	-0.81	-0.62	0.19
2024-11-06	-0.98	-0.71	0.27
2024-08-05	-0.85	-1.07	-0.22
2024-05-09	-0.76	-1.11	-0.35
2024-02-27	0.36	-0.31	-0.67
2023-11-07	-0.77	-0.4	0.37
2023-08-03	-0.91	-0.37	0.54